Exclusive Summary

• - Core patents expired around 2010, with broad global genericization and short registration pathways.
• - Breast cancer has ~2.3–2.5M new cases annually; ~70% are HR+, mostly postmenopausal, with long treatment duration (5–10 years).
• - Listed on the WHO Model List and recommended by NCCN/ESMO/ASCO as a first-line endocrine option for postmenopausal HR+ disease.
• - Highly competitive with many generic MA holders, yet room remains for supply reliability, packaging, and tender-oriented differentiation.
• - >90% price erosion vs originator; monthly cost is typically <USD 5 in mature markets, enabling rapid uptake and payer acceptance.